2019-2015年
| Receptor Antagonists Bearing a Pentafluorosulfanyl (SF5) Group. Mori, S.; Tsuemoto, N.; Kasagawa, T.; Nakano, E.; Fujii, S.; Kagechika, H. Chem. Pharm. Bull. 2019, 67(12), 1278-1283. DOI: 10.1248/cpb.c19-00522. |
| A Polarity-Sensitive Fluorescent Amino Acid and its Incorporation into Peptides for the Ratiometric Detection of Biomolecular Interactions. Yokoo, H.; Kagechika, H.; Ohsaki, A; Hirano T. A ChemPlusChem 2019, 84, 1716-1719. DOI: 10.1002/cplu.201900489 |
| A New LC-MS Assay for the Quantitative Analysis of Vitamin K Metabolites in Human Urine. McDonald, M. G.; Yeung, C. K.; Teitelbaum, A. M.; Johnson, A. L.; Fujii, S.; Kagechika, H.; Rettie, A. E. J. Lipid Res. 2019, 60(4), 892-899. DOI: 10.1194/jlr.D087916 |
| Two new alkaloids from Crinum asiaticum var. japonicum. Endo, Y.; Sugiura, Y.; Funasaki, M.; Kagechika, H.; Ishibashi, M.; Ohsaki, A. J. Nat. Med. 2019, 73, 648-652. DOI: 10.1007/s11418-019-01304-9 |
| Design, synthesis and biological evaluation of novel nonsteroidal progesterone receptor antagonists based on phenylamino-1,3,5-tirazine scaffold. Kaitoh, K.; Nakatsu, A.; Mori, S.; Kagechika, H.; Hashimoto, Y.; Fujii,S. Chem. Pharm. Bull. 2019, 67(6), 566-575. DOI: 10.1248/cpb.c19-00094 |
| A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1. Park, S. W.; Nhieu, J.; Persaud, S. D.; Miller, M. C.; Xia, Y.; Lin, Y.-W.; Lin, Y.-L.; Kagechika, H.; Mayo, K. H.; Wei, L/-N. Sci. Rep. 2019, 9, 10929. DOI: 10.1038/s41598-019-47354-7 |
| Development of Novel Lithocholic Acid Derivatives as Vitamin D Receptor Agonists. Bioorg. Masuno, H.; Kazui, Y.; Tanatani, A.; Fujii, S.; Kawachi, E.; Ikura, T.; Ito, N.; Yamamoto, K.; Kagechika, H. Bioorg. Med. Chem. 2019, 27, 3674-3681. DOI: 10.1016/j.bmc.2019.07.003 |
| Structural development of a type-1 ryanodine receptor (RyR1) Ca2+-release channel inhibitor guided by endoplasmic reticulum Ca2+ assay. Mori, S.; Iinuma, H.; Manaka, N.; Ishigami-Yuasa, M.; Murayama, T.; Nishijima, Y.; Sakurai, A.; Arai, R.; Kurebayashi, N.; Sakurai, T.; Kagechika, H. Eur. J. Med. Chem. 2019, 179, 837-848. DOI: 10.1016/j.ejmech.2019.06.076 |
| Design and synthesis of cyclohexyl-p-carborane derivatives as a new class of progesterone receptor antagonists. Fujii, S.; Yanagida, N.; Mori, S.; Kawachi, E.; Kagechika, H. Heterocycles 2019, 99, 425-445. DOI: 10.3987/COM-18-S(F)38 |
| Spontaneous Chiral Resolution of N,N’-Diarylsquaramides : Formation of Various Types of One-handed Helical Networks During Crystallization. Kanda, M.; Urushibara, Ko.; Park, S.; Fujii, S.; Masu, H.; Katagiri, K.; Azumaya, I.; Kagechika, H.; Tanatani, A. Tetrahedron 2019, 75, 2771-2777. DOI: 10.1016/j.tet.2019.03.049 |
| Class IIb HDAC inhibition enhances the inhibitory effect of Am80, a synthetic retinoid, in prostate cancer. Ishigami-Yuasa, M.; Ekimoto, H.; Kagechika, H. Biol. Pharm. Bull. 2019, 42, 448-452. DOI: 10.1248/bpb.b18-00782 Highlighted Paper selected by Editor-in-Chie |
| Structure-Activity Relationship of Novel Androgen Receptor Antagonists Bearing a (Benzoylaminophenoxy)phenol Pharmacophore. Kazui, Y.; Fujii, S.*; Yamada, A.; Ishigami-Yuasa, M.; Kagechika, H.; Tanatani, A Bioorg. Med. Chem. 2018, 26, 5118-5127. DOI: 10.1016/j.bmc.2018.09.008 |
| Prevention of acute liver injury by suppressing plasma kallikrein-dependent activation of latent TGF-b. Li, M.; Qin, X.-Y.; Furutani, Y.; Inoue, I.; Sekihara, S.; Kagechika, H.; Kojima S. Biochem. Biophys. Res. Chem. 2018, 504, 857-864. DOI: 10.1016/j.bbrc.2018.09.026 |
| HX600, a synthetic agonist for RXR-Nurr1 heterodimer complex, preventsischemia-induced neuronal damage. Loppi, S.; Kolosowska, N.; K?rkk?inen, O.; Korhonen, P.; Huuskonen, M.; Grubman, A.; Dhungana, H.; Wojciechowski, S.; Pomeshchik, Y.; Giordano, M.; Kagechika, H.; White, A.; Auriola, S.; Koistinaho, J.; Landreth, G.; Hanhineva, K.; Kanninen, K.; Malm, T. Brain Behav. Immunol. 2018, 73, 670-681. DOI: 10.1016/j.bbi.2018.07.021 |
| Development of novel inhibitors for histone methyltransferase SET7/9 based on cyproheptadine． Hirano, T.; Fujiwara, T.; Niwa, H.; Hirano, M.; Ohira, K.; Okazaki, Y.; Sato, S.; Umehara, T.; Maemoto, Y.; Ito, A.; Yoshida, M.; Kagechika, H. ChemMedChem 2018, 13, 1530-1540. DOI: 10.1002/cmdc.201800233 |
| Novel non-steroidal progesterone receptor (PR) antagonists with a phenanthridinone skeleton. Nishiyama, Y.; Mori, S.; Makishima, M.; Fujii, S.; Kagechika, H.; Hashimoto, Y.; Ishikawa, M. ACS Med. Chem. Lett. 2018, 9, 641-645. DOI: 10.1021/acsmedchemlett.8b00058 |
| Development of biotin-retinoid conjugates as chemical probes for analysis of retinoid function. Fujii, S.; Mori, S.; Kagechika, H.; Parra, M. A. M.*; Gronemeyer, H. Bioorg. Med. Chem. Lett. 2018, 28, 2442-2445. DOI: 10.1016/j.bmcl.2018.06.011 |
| Efficient High-Throughput Screening by Endoplasmic Reticulum Ca2+ Measurement to Identify Inhibitors of Ryanodine Receptor Ca2+-Release Channels. Murayama, T.; Kurebayashi, Ishigami-Yuasa, M.; Mori, A.; Suzuki, Y.; Akima, R.; Ogawa, H.; Suzuki, J.; Kanemaru, K.; Oyamada, H.; Kiuchi, Y.; Iino, K.; Kagechika, H.; Sakurai, T. Mol. Pharmacol. 2018, 94, 722-730. DOI: 10.1124/mol.117.111468 |
| Characterization and comparison of transcriptional activities of the retinoid X receptors by various organotin compounds in three prosobranch gastropods; Thais clavigera, Nucella lapillus and Babylonia japonica. Urushitani, H.; Katsu, Y.; Kagechika, H.; Sousa, A. C. A.; Barroso, C. M.; Ohta, Y.; Shiraishi, H.; Iguchi, T.; Horiguchi, T. Aquatic Toxicol. 2018, 199, 103-155. DOI: 10.1016/j.aquatox.2018.03.029 |
| Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. Qin, X.-Y.; Suzuki, H.; Honda, M.; Okada, H.; Kaneko, S.; Inoue, I.; Ebisui, E.; Hashimoto, K.; Carninci, P.; Kanki, K.; Tatsukawa, H.; Ishibashi, N.; Masaki, T.; Matsuura, T.; Kagechika, H.; Toriguchi, K.; Hatano, E.; Shirakami, Y.; Shiota, G.; Shimizu, M.; Moriwaki, H.; Kojima, S. Proc. Nat. Acad. Sci. USA 2018, 115 (19), 4969-4974. DOI: 10.1073/pnas.1802279115 |
| AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipid us. Ando, F.; Mori, S.; Yui, N.; Morimoto, T.; Nomura, N.; Sohara, E.; Rai, T.; Sasaki, S.; Kondo, Y.; Kagechika, H.; Uchida, S. Nature Commun. 2018, 9, 1411. DOI: https://doi.org/10.1038/s41467-018-03771-2 |
| Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models. Shimada, S.; Akiyama, Y.; Mogushi, K.; Ishigami-Yuasa, M.; Kagechika, H.; Nagasaki, H.; Fukamachi, H.; Yuasa, Y.; Tanaka, S. Br J Cancer 2018, 118 (7), 972-984. DOI: 10.1038/s41416-018-0008-y |
| Conformational Properties of Aromatic Oligoamides Bearing Pyrrole Rings. Tojo, Y.; Urushibara, K.; Yamamoto, S.; Mori, H.; Masu, H.; Kudo, M.; Hirano, T.; Azumaya, I.; Kagechika, H.; Tanatani, A. J. Org. Chem. 2018, 83, 4606-4617. DOI: 10.1021/acs.joc.8b00349 |
| Unique properties of 1,5-naphthyridin-2(1H)-one derivatives as environmental-polarity-sensitive fluorescent dyes. Yokoo, H.; Ohsaki, A.; Kagechika, H.; Hirano, T. Eur. J. Org. Chem. 2018, 16, 679-687. DOI: https://doi.org/10.1002/ejoc.201701609 |
| Novel YAP1 Activator, Identified by Transcription-Based Functional Screen, Limits Multiple Myeloma Growth. Maruyama, J.; Inami, K.; Michishita, F.; Jiang, X. L.; Iwasa, H.; Nakagawa, K.; Ishigami-Yuasa, M.; Kagechika, H.; Miyamura, N.; Hirayama, J.; Nishina, H.; Nogawa, D.; Yamamoto, K.; Hata, Y. Mol. Cancer Res. 2018, 16, 197-211. DOI: 10.1158/1541-7786.MCR-17-0382 |
| Sucupiranins A－L, Furanocassane Diterpenoids from the Seeds of Bowdichia virgilioides. Endo,Y.; Kasahara,T.; Harada,K.; Kubo, M.; Etoh, T.; Ishibashi, M.; Ishiyama, A.; Iwatsuki, M.; Otoguro, K.; Ohmura, S.; Akisue, G.; Hirano, T.; Kagechika, H.; Fukuyama, Y.; Ohsaki, A. J. Nat. Prod 2017, 80, 3120-3127. DOI: 10.1021/acs.jnatprod.7b00249 |
| Modulating Biocatalytic Activity toward Sterically Bulky Substrates in CO2-Expanded Biobased Liquids by Tuning the Physicochemical Properties. Hoang, H. N.; Granero-Fernandez, E.; Yamada, S.; Mori, S.; Kagechika, H.; Medina-Gonzalez, Y.; Matsuda, T. ACS Sus. Chem. Eng. 2017, 5, 11051-11059. DOI: 10.1021/acssuschemeng.7b03018 |
| Crystal Engineering of N,N’-Diphenylurea Compounds Featuring Phenyl-Perfluorophenyl Interaction. Yamasaki, R.; Iida, M.; Ito, A.; Fukuda, K.; Tanatani, A.; Kagechika, H., Masu, H. Okamoto, I. Crystal Growth Des. 2017, 17, 5858-5866. DOI: 10.1021/acs.cgd.7b00951 |
| Novel non-steroidal progesterone receptor ligands based on m-carborane containing a secondary alcohol: effect of chirality on ligand activity. Mori, S.; Takagaki, R.; Fujii, S.; Urushibara, K.; Tanatani, A.; Kagechika, H. Chem. Pharm. Bull. 2017, 65, 1051-1057. DOI: 10.1248/cpb.c17-00544 |
| Suppressive effects of RXR agonist PA024 on adrenal CYP11B2 expression, aldosterone secretion and blood pressure. Suzuki, D.; Saito-Hakoda, A.; Ito, R.; Shimizu, K.; Parvin, R.; Shimada, H.; Noro, E.; Suzuki, S.; Fujiwara, I.; Kagechika, H.; Rainey, W. E.; Kure, S.; Ito, S.; Yokoyama, A.; Sugawara, A. Plos ONE 2017, 12, e0181055. DOI: 10.1371/journal.pone.0181055 |
| Selective Reagent for Detection of N-ε-Monomethylation of a Peptide Lysine Residue through SNAr Reaction. Mori, S.; Hirano T.; Takaguchi, A.; Fujiwara, T.; Okazaki, Y.; Kagechika, H. Eur. J. Org. Chem. 2017, 25, 3606-3611. DOI: 10.1002/ejoc.201700488 |
| Development of WNK signaling inhibitors as a new class of antihypertensive drugs. Bioorg. Ishigami-Yuasa, M.; Watanabe, Y.; Mori, T.; Masuno, H.; Fujii, S.; Kikuchi, E.; Uchida, S.; Kagechika, H. Med. Chem. 2017, 25, 3845-3852. DOI: 10.1016/j.bmc.2017.05.034 |
| Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy. Yoshizaki, Y.; Mori, T.; Ishigami-Yuasa, M.; Kikuchi, E.; Takahashi, D.; Zeniya, M.; Nomura, N.; Mori, Y.; Araki, Y.; Ando, F.; Mandai, S.; Kasagi, Y.; Arai, Y.; Sasaki, E.; Yoshida, S.; Kagechika, H.; Rai, T.; Uchida, S.; Sohara, E. Sci. Rep. 2017, 7, 3945. DOI: 10.1038/s41598-017-04233-3 |
| Development of nonsteroidal glucocorticoid receptor modulators based on N-benzyl-N-(4-phenoxyphenyl)benzenesulfonamide scaffold. Yoshioka, H.; Yamada, A.; Nishiyama, Y.; Kagechika, H.; Hashimoto, Y.; Fujii, S. Bioorg. Med. Chem. 2017, 25, 3461-3470. DOI: 10.1016/j.bmc.2017.04.032 |
| Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression. Nguyen, B. N.; Okuno, Y.; Ajiro, M.; Iida, K.; Denawa, M.; Yamamoto, M.; Sakamoto, N.; Kagechika, H.; Hagiwara, M. J. Med. Virol. 2017, 89, 1224-1234. DOI: 10.1002/jmv.24739 |
| CO2-expanded bio-based liquids as novel solvents for enantioselective biocatalysis. Hoang, H. N.; Nagashima, Y.; Mori, S.; Kagechika, H.; Matsuda, T. Tetrahedron 2017, 73, 2984-2989. DOI: 10.1016/j.tet.2017.04.024 |
| 9-cis Retinoic acid modulates myotrophin expression and its miR in physiological and pathophysiological cell models. Perri, M.; Caroleo, Nannan M. C.; Gallelli, L. L.; De Sarro, G.; Kagechika, H.; Cione, E. Exp. Cell Res. 2017, 354, 25-30. DOI: 10.1016/j.yexcr.2017.03.022 |
| The receptor subtype selectivity of retinoid X and retinoic acid receptors via quantum mechanics. Tsuji, M.; Shudo, K.; Kagechika, H. FEBS Open Bio. 2017, 7, 391-396. DOI: 10.1002/2211-5463.12188 |
| Down-regulation of histone deacetylase 4, －5 and －6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin. Oya, Y.; Mondal, A.; Rawangkan, A.; Umsumarng, S.; Iida, K.; Watanabe, T.; Kanno, M.; Suzuki, K.; Li, Z.; Kagechika, H.; Shudo, K.; Fujiki, H.; Suganuma, M. J. Nutr. Biochem. 2017, 42, 7-16. DOI: 10.1016/j.jnutbio.2016.12.015 |
| Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription. Handa, N.; Umehara, T.; Sonoda, T.; Ogawa, K.; Tariq, M.; Nishino, N.; Dan, S.; Kagechika, H.; Yamori, T.; Yokoyama, S.; Yoshida, M. J. Med. Chem. 2016, 59, 3650-3660. DOI: 10.1021/acs.jmedchem.5b01732 |
| Development of an “OFF-ON-OFF” fluorescent pH sensor suitable for the study of intracellular pH. Hirano, T.; Noji, Y.; Shiraishi, T.; Ishigami-Yuasa, M.; Kagechika, H. Tetrahedron 2016, 72, 4925-4930. DOI: https://doi.org/10.1016/j.tet.2016.06.065 |
| Validation of the chemical compound library screening for TAZ inhibitors by use of green fluorescence protein-fused TAZ. Nagashima, S.; Maruyama, J.; Kawano, S.; Iwasa, H.; Nakagawa, K.; Ishigami-Yuasa, M.; Kagechika, H.; Nishina, H.; Hata, Y. Cancer Sci. 2016, 107, 791-802. DOI: 10.1111/cas.12936 |
| Steric structure?activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9. Fujiwara, T.; Ohira, K.; Urushibara, K.; Ito, A.; Yoshida, M.; Kanai, M.; Tanatani, A.; Kagechika, H.; Hirano, T. Bioorg. Med. Chem. 2016, 24, 4318-4323. DOI: 10.1016/j.bmc.2016.07.024 |
| All trans-retinoic acid analogs promote cancer cell apoptosis through non-genomic Crabp1 mediating ERK1/2 phosphorylation. Persaud, S. D.; Park, S. W.; Ishigami-Yuasa, M.; Koyano-Nakagawa, N.;, Kagechika, H.; Wei, L.-N. Sci. Rep. 2016, 6, 22396. DOI: 10.1038/srep22396 |
| Two new diterpenoids from Salvia przewarskii. Tsukada, H.; Kawabeb, H.; Ohtakac, A.; Saitod, Y.: Okamotoe, Y.: Torie, M.; Kagechika, H.; Hirotab, H.; Gongf, X.; Kurodac, C.; Ohsaki, A. Nat. Prod. Commun. 2016, 11 (2), 135-272. |
| Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Shrestha, R.; Tatsukawa, H.; Shrestha, R.; Ishibashi, N.; Matsuura, T.; Kagechika, H.; Kose, S.; Hitomi, K.; Imamoto, N.; Kojima, S. Cell Death & Diseases 2015, 6, e2002. DOI: 10.1038/cddis.2015.339 |
| Effects of RXR Agonists on Cell Proliferation/Apoptosis and ACTH Secretion/Pomc Expression. Saito-Hakoda, A.; Uruno, A.; Yokoyama, A.; Shimizu, K.; Parvin, R.; Kudo, M.; Saito-Ito, T.; Sato, I.; Kogure, N.; S uzuki, D.; Shimada, H.; Yoshikawa, T .; Fujiwara, I.; Kagechika, H.; Iwasaki, Y.; Kure, S.; Ito, S.; Sugawara, A. Plos ONE 2015, 10, e0141960. DOI: 10.1371/journal.pone.0145286 |
| A Modified Murine Embryonic Stem Cell Test for Evaluating the Teratogenic Effects of Drugs on Early Embryogenesis. Yu. R.: Miyamura, N.; Okamoto-Uchida, Y.; Arima, N.; Ishigami-Yuasa, M.; Kagechika, H.; Nishina, H. Plos ONE 2015, 10, e0145286. DOI: 10.1248/bpb.b18-00782 |
| A cell-based screening for TAZ activators identifies ethacridine, a widely used antiseptic and ab ortifacient, as a compound that promotes dephosphorylation of TAZ and inhibits adipogenesis in C3H10T1/2 cells. Kawano, S.; Maruyama, J.; Nagashima, S.; Inami, K.; Qiu, W.; Iwasa, H.; Nakagawa, K.; Ishigami-Yuasa, M.; Kagechika, H.; Nishina, H.; Hata, Y.J. Biochem. 2015, 158, 413-420. DOI: 10.1093/jb/mvv051 |
| 6-Arylcoumarins: versatile scaffolds for fluorescent sensors. Shiraishi, T.; Kagechika, H.; Hirano, T.* New J. Chem. 2015, 39, 8389-8396. DOI: 10.1039/c5nj01609f |
| Docking simulations suggest that all-trans retinoic acid could bind to retinoid X receptors. Tsuji, M.; Shudo, K.; Kagechika, H. J. Comput. Aided Mol. Des. 2015, 29, 975-988. DOI: 10.1007/s10822-015-9869-9 |
| A new cell-based assay to evaluate myogenesis in mouse myoblast C2C12 cells. Kodaka, M.; Yang, Z.; Nakagawa, K.; Maruyama, J.; Xu, X.; Sarkar, A.; Ichimura, A.; Nasu, Y.; Ozawa, T.; Iwasa, H.; Ishigami-Yuasa, M.; Ito, S.; Kagechika, H.; Hata, Y. Exp. Cell. Res. 2015, 336, 171-181. DOI: 10.1016/j.yexcr.2015.06.015 |
| Carboxylic derivatives of vitamin K2 inhibit hepatocel lular carcinoma cell growth through caspase/transglutaminase-related signaling pathways. Qin, X.-Y.; Fujii, S.; Shimizu, A.; Kagechika, H.; KOJIMA, S. J. Nutr. Sci.Vitaminol. 2015, 61, 285-290. DOI: 10.3177/jnsv.61.285. |
| Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel an drogen receptor antagonists. Inoue, K.; Urushibara, K.; Kanai, M.; Yura, K.; Fujii, S.; Ishigami-Yuasa, M.; Hashimoto, Y.; Mori, S.; Kawachi, E.; Matsumura, M.; Hirano, T.; Kagechik, H.; Tanatani, A. Eur. J. Med. Chem. 2015, 102, 310-319. DOI: 110.1016/j.ejmech.2015.08.002 |
| Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride Transporters. Nishiyama, S.; Urushibara, K.; Masu, H.; Azumaya, I.; Kagechika, H. Tanatani, A. J. Am. Soc. Nephrol. 2015, 26, 1525-1536. DOI: 10.1681/ASN.2014060560. |
| Conformational and chiral properties of cyclic-tri(N-methyl-meta-benzamide) bearing amidino groups. Inoue, K.; Urushibara, K.; Kanai, M.; Yura, K.; Fujii, S.; Ishigami-Yuasa, M.; Hashimoto, Y.; Mori, S.; Kawachi, E.; Matsumura, M.; Hirano, T.; Kagechik, H.; Tanatani, A. Chirality 2015, 27, 487-491. DOI: 10.1002/chir.22476 |
| Systematic synthesis and anti-inflammatory activity of ω-carboxylated menaquinone derivatives - Investigations on identified and putative vitamin K2 metabolites. Fujii, S.; Shimizu, A.; Takeda, N.; Oguchi, K.; Katsurai, T.; Shirakawa, H.; Komai, M.; Kagechika, H. Bioorg. Med. Chem. 2015, 23, 2344-2352. DOI: 10.1016/j.bmc.2015.03.070 |
| Retinoic acid receptor signaling is required to maintain glucose-stimulated insulin secretion and b-cell mass. Brun, P.-J.; Grijalva, A.; Rausch, R.; Watson, E.; Yuen, J. J.; Das, B. C.; Shudo, K.; Kagechika, H.; Leibel, R. L.; Blaner, W. S. FASEB J. 2015, 29, 671-683. DOI: 10.1096/fj.14-256743 |
| Development of 1,3-diphenyladamantane derivatives as nonstero idal progesterone receptor antagonists. Mori, S.; Takeuchi, Y.; Tanatani, A.; Kagechika, H.; Fujii, S. Bioorg. Med. Chem. 2015, 23, 803-809. DOI: 10.1016/j.bmc.2014.12.047 |